Clover Announces Completion of US FDA IND Submission for Second Pivotal Phase 3 Clinical Trial of CBL-514 Injection for Abdominal Fat Reduction
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Clover Biopharmaceuticals announced that the second pivotal Phase 3 clinical trial (SUPREME-02, code CBL-0302) for its new drug CBL-514 injection, used for reducing abdominal subcutaneous fat, has completed its Investigational New Drug (IND) submission to the US FDA on April 20, 115 (2026).